Stage 2 Mesothelioma News
- Oncolytics Biotech Inc. Announces 2008 Second Quarter Results Tuesday, July 29, 2008 @ 8:14PM Oncolytics Biotech Inc. today announced its financial results and highlights for the three and six month periods ended June 30, 2008.
- JapanToday : Japan News and Discussion ジャパントゥデイ:日本のニュースを英語で読む Monday, July 14, 2008 @ 8:47PMWhen one thinks of Oji Paper, Japan’s largest paper manufacturing company (in terms of consolidated sales), the image is of vast green forests in Hokkaido, excellent paper-making technology, and the guiding hand of Eichi Shibusawa.
- JapanToday : Japan News and Discussion ジャパントゥデイ:日本のニュースを英語で読む Monday, July 14, 2008 @ 8:47PMWhen one thinks of Oji Paper, Japan’s largest paper manufacturing company (in terms of consolidated sales), the image is of vast green forests in Hokkaido, excellent paper-making technology, and the guiding hand of Eichi Shibusawa.
- JapanToday : Japan News and Discussion ジャパントゥデイ:日本のニュースを英語で読む Monday, July 14, 2008 @ 8:47PMWhen one thinks of Oji Paper, Japan’s largest paper manufacturing company (in terms of consolidated sales), the image is of vast green forests in Hokkaido, excellent paper-making technology, and the guiding hand of Eichi Shibusawa.
- JapanToday : Japan News and Discussion ジャパントゥデイ:日本のニュースを英語で読む Monday, July 14, 2008 @ 8:47PMWhen one thinks of Oji Paper, Japan’s largest paper manufacturing company (in terms of consolidated sales), the image is of vast green forests in Hokkaido, excellent paper-making technology, and the guiding hand of Eichi Shibusawa.
- JapanToday: Japan News and Discussion ジャパントゥデイ:日本のニュースを英語で読む Monday, July 14, 2008 @ 8:47PMWhen one thinks of Oji Paper, Japan’s largest paper manufacturing company (in terms of consolidated sales), the image is of vast green forests in Hokkaido, excellent paper-making technology, and the guiding hand of Eichi Shibusawa.
- Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program Wednesday, April 2, 2008 @ 8:30AM Alfacell Corporation today announced that it has confirmed that 316 evaluable events have occurred in the confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE , for the treatment of patients with unresectable malignant mesothelioma .
- Staff Writer Tuesday, January 15, 2008 @ 8:48PMAlfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million.
- CuraGen And TopoTarget Announce Initiation Of An NCI-sponsored Phase II Clinical Trial Of Belinostat For Thymoma And ... Thursday, December 20, 2007 @ 4:17AMCuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced the initiation of patient dosing in a Phase II open-label, multi-center clinical trial evaluating the efficacy and safety of int [click link for full article]
